A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults

Documents similaires

• Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study
  par: Jessica Ailani, et autres
  Publié: (2025)
• Effects of multiple‐dose administration of zavegepant nasal spray on the single‐dose pharmacokinetics of ethinyl estradiol‐levonorgestrel
  par: Rajinder Bhardwaj, et autres
  Publié: (2024)
• A phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women
  par: Abhijeet Jakate, et autres
  Publié: (2026)
• Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo‐controlled trials
  par: Richard Bertz, et autres
  Publié: (2025)
• Milk and plasma pharmacokinetics of single‐dose ubrogepant in healthy lactating women
  par: Ramesh R. Boinpally, et autres
  Publié: (2025)